BioNTech SE BNTX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -414.65% | -78.40% | -76.39% | -26.46% | 29.76% |
| Total Depreciation and Amortization | 215.00% | 77.27% | 23.80% | 19.56% | -21.22% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 407.32% | 483.76% | 290.06% | 90.80% | -96.85% |
| Change in Net Operating Assets | 193.76% | 87.44% | -51.92% | -93.07% | -136.41% |
| Cash from Operations | 142.81% | 455.36% | 193.17% | -114.59% | -157.75% |
| Capital Expenditure | -5.26% | 28.57% | 36.19% | 40.68% | 24.21% |
| Sale of Property, Plant, and Equipment | 356.99% | 259.20% | 301.35% | 859.51% | 907.76% |
| Cash Acquisitions | 473.15% | 473.15% | -- | -- | 77.47% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -165.71% | -169.14% | -55.36% | 119.61% | 132.28% |
| Cash from Investing | -173.42% | -179.50% | -32.79% | 113.82% | 124.69% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -40.90% | -7.51% | -25.49% | 9.82% | 19.27% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -172.11% | 74.30% | -20.42% | 8.70% | 88.05% |
| Foreign Exchange rate Adjustments | -672.93% | -99.89% | -289.94% | 88.51% | 106.83% |
| Miscellaneous Cash Flow Adjustments | 34.31% | -40.50% | 136.56% | -109.51% | -84.54% |
| Net Change in Cash | -332.45% | -121.68% | -18.60% | 111.43% | 96.61% |